XNCR - Xencor Inc logo

Xencor Inc

XNCR

Xencor Inc is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibodies for cancer and autoimmune diseases. Its pipeline includes treatments for conditions like renal cell carcinoma, ovarian cancer, and rheumatoid arthritis.

โš•๏ธ Healthcare NASDAQ Listed 2013 $ USD
$1,000 invested 10 years ago โ†’$1,182today

Score Overview

1 Year
Score
Net Growth-77.68%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-57.20%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score1.8
Net Growth-297.66%
Net Trend20%
Net Income Consistencyโ€”
Rev Growth-80.46%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-6x
Net Trend30%
Net Income Consistency
Rev Growth-38.58%
Rev Trend50%
Revenue Consistency
All Time
Score
Net Growth-171.04%
Net Trend38%
Net Income Consistency
Rev Growth428.43%
Rev Trend54%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Xencor Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. XNCR does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 25.18โ€”
1 Year2025-10-23
$ 12.34104.05%
5 Years2021-10-22
$ 39.24-35.83%
10 Years2016-10-21
$ 21.3018.22%
All Time2013-12-03
$ 8.34201.92%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 53M-$ 163M$ 377M
2025$ 125M-$ 91M$ 547M
2024$ 110M-$ 232M$ 497M
2023$ 168M-$ 126M$ 593M
2022$ 164M-$ 55M$ 623M
2021$ 275M$ 82M$ 334M
2020$ 122M-$ 63M$ 603M
2019$ 156M$ 26M$ 527M
2018$ 40M-$ 70M$ 294M
2017$ 35M-$ 48M$ 224M
2016$ 87M$ 23M$ 130M
2015$ 27M-$ 17M$ 96M
2014$ 9M-$ 16M$ 54M
IPO2013$ 10M-$ 60M$ 77M
XNCR - Xencor Inc logo

Xencor Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 122M to $ 125M and net income went from -$ 63M to -$ 91M. Revenue increased in 2 of those 5 years; net income in 1.

Across Xencor Inc's full reported history, from 2013 to 2025, revenue grew from $ 10M to $ 125M and net income went from -$ 60M to -$ 91M. Revenue increased in 54% of the years measured; net income in 38%.

Xencor Inc currently holds a 5-year HDB Score of 1.8 out of 10. How the HDB Score is calculated.

Membership

Explore XNCR with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies